https://vital.lib.tsu.ru/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000662056 Wed 25 Sep 2019 11:02:45 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/koha:000925698 Wed 21 Dec 2022 15:18:36 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000615947 Tue 28 Nov 2017 10:27:59 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000651571 C (rs2071559) and KDR 1192G>A (rs2305948) polymorphisms. The pCR was used as an end-point in the treatment efficacy analysis. In the univariate analysis, the pCR rate was strongly associated with young age (P = 0.004), high Ki67 expression (P = 0.012), lymph node negativity (P = 0.023) as well as with positive VEGFR2 expression (P = 0.019) and the CAX regimen (P = 0.005). In the multivariate analysis, only patient’s age (P = 0.005) and pre-NCT VEGFR2 expression (P = 0.048) remained significant predictors of pCR. The pCR rate was higher in the CAX-treated patients than that in the FAC-treated patients (P = 0.005). Our results revealed that − 604TT genotype of rs2071559 and age < 50 years were correlated with a pCR in the CAX-treated patients. VEGFR2 expression in pre-NCT tumors and KDR gene polymorphism can be considered as additional predictive molecular markers of pCR in Russian TN breast cancer patients treated with NCT.]]> Tue 09 Apr 2019 14:51:05 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000574849 Tue 02 May 2017 12:39:09 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/koha:000896012 Thu 16 Jun 2022 13:20:50 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000577681 Sat 29 Jul 2017 18:30:36 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000787797 Mon 23 Nov 2020 09:53:07 KRAT ]]> https://vital.lib.tsu.ru/vital/access/manager/Repository/koha:001003659 Mon 19 Jun 2023 16:12:46 KRAT ]]>